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Introduction
For more than two decades, computerized health databases containing medical care data have been considered important to understanding the realworld use, benefits, and adverse outcomes associated with pharmaceutical and biological therapies. 1 Health databases routinely record information on prescriptions written or dispensed as well as outpatient or hospital diagnoses, procedures, and interventions. These data are collected for administrative or insurance management purposes in claims databases or as part of the electronic medical records in which detailed clinical information is recorded by health care practitioners. These data sources appear to have become the cornerstone of pharmacoepidemiology research, yet almost no quantitative research has been conducted to document this impression. This study aimed to quantify and characterize the use of automated health care databases for pharmacoepidemiology research over the past decade. We defined a database as any longitudinal electronic collection of medical and/or administrative information for individual patients. Using a predefined abstraction process, the four of us who are epidemiologists abstracted data from studies conducted in databases. We abstracted the following information: ICPE year; abstract number; author name; study objective; number of databases involved; and name, country, and world region of the database. Study objectives were classified into five categories: safety endpoint, drug utilization or risk minimization evaluation, disease epidemiology, validation of database variables (e.g., diagnostic codes or algorithms to identify study endpoints, covariates, and exposures), and other (e.g., methodological issues, effectiveness, surveillance studies not involving a prespecified endpoint). We defined a multipledatabase study as a study that used two or more databases to select the study subjects. Studies using database linkage to obtain additional information on study subjects already identified in a single database were not considered multiple-database studies. Finally, studies were not considered to be database studies if they were field studies (defined as a study conducted by recruiting patients to participate in the study), health economic studies, or studies of spontaneous reports that were conducted in databases.
Methods
Each research epidemiologist reviewed and abstracted a set of abstracts, and each set was additionally reviewed by a different epidemiologist. The study team met regularly to discuss the consistency of abstractions. We contacted the abstract authors and reviewed published studies to collect essential information not included in the published abstract.
Additionally, we conducted a descriptive analysis and reported the number and percentage of database abstracts by year, study objective, country, and world region. We also enumerated and characterized the multiple-database studies.
Results
The total number of published ICPE abstracts The combined categories of studies on safety endpoints and drug utilization/risk minimization accounted for 84.2 percent of all database abstracts in 2000 and 65.6 percent in 2011. Studies categorized as "other" included studies on epidemiological methods, statistical methods, and effectiveness in 2000; in 2011, "other" studies included studies on epidemiological methods, statistical methods, effectiveness, surveillance, and "other"-not falling into any of the previous categories (Table 1) . Most studies were single-database studies (Table 2) , but the number of abstracts describing multipledatabase studies increased from 9 (6.5 percent of all database abstracts) in 2000 to 43 (11.9 percent) in 2011. Of the 9 multiple-database abstracts published in 2000, only 1 study (11.1 percent) was conducted in multiple countries (data not shown). However, in 2011, 17 of 43 (39.5 percent) multiple-database abstracts involved more than one country. For the database abstracts, the overall number of database source countries increased from 14 to 22 (Figure 2 
Discussion
Over the past decade, the number of pharmacoepidemiology studies conducted using automated health care databases and presented at ICPE has experienced a remarkable expansion, and the number of countries where pharmacoepidemiology research is being conducted using databases has almost doubled. The Asia Pacific region had the largest percentage increase in abstracts on database studies. Studies using multiple databases from within a single country and across multiple countries have become more common. Database validation studies also increased between 2000 and 2011, representing almost 11 percent of the total in 2011. This is an encouraging finding in that the importance of validation to improving the quality of research is generally recognized. Because the ICPE was held in Europe in 2000 and in North America in 2011, the different locations could account for part of the results, as it is likely that regional participation, including the number of abstracts, increases when the meeting is conducted in a particular world region.
Overall, the findings suggest that the use of automated health care databases in pharmacoepidemiology research is growing in many countries. The different types of database studies and the number of studies conducted using multiple databases is also increasing, suggesting that larger study populations and greater collaboration among investigators are becoming more common.
